Radovich Peter

MIRM President/COO sold 16,515 shares at $91.98 on 2026-03-16; stock now $96.55. Prior sells poorly timed (90d avg +0.9%).

Peter Radovich sold 16,515 shares (16.5K shares) of Mirum Pharmaceuticals at $91.98, reducing his holdings by -29.1% to 40,272 shares (40.3K shares). His cross-ticker track record shows a 90-day well-timed rate of 0.00%, indicating his prior sells across all tickers were poorly timed on average. At the same ticker (MIRM), his 2 prior sales in 2025 posted average 90-day returns of +0.9%, confirming a pattern of selling before rallies rather than declines. The company trades at a P/E of 254.08 and is currently unprofitable (full-year net income was negative), though revenue grew +54.7% year-over-year. The stock has declined -6.4% over the past 30 days and is -11.1% from its 52-week high of $108.62.

MIRM President/COO Radovich sells 14,850 shares (55.1% of holdings) for $676.9K at avg $45.58; stock down 16.0% from 52-week high.

Radovich executed 2 separate sales totaling 14,850 shares for $676,928.28 on March 4, 2025, reducing his holdings by 55.1% from 26,961 shares to 12,111 shares. The company is scaling rapidly (revenue growth +80.8% annually) but remains unprofitable with full-year net income of $-14,235,000.00, and the stock has declined 8.1% over the past 30 days and 16.0% from its 52-week high of $53.16. This substantial reduction in the President and COO's ownership stake during a period of stock price weakness and ongoing losses merits investor scrutiny, particularly given the magnitude of the disposal relative to his total pre-transaction holdings.